Conceptualizing a Model: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2

Caro, 2012, Modeling good research practices—overview: a report of the ISPOR-SMDM modeling good research practices task force-1, Value Health, 15, 796, 10.1016/j.jval.2012.06.012 Siebert, 2012, State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force-3, Value Health, 15, 812, 10.1016/j.jval.2012.06.014 Karnon, 2012, Modeling using discrete event simulation: a report of the ISPOR-SMDM modeling good research practices task force-4, Value Health, 15, 821, 10.1016/j.jval.2012.04.013 Pitman, 2012, Dynamic transmission modeling: a report of the ISPOR-SMDM modeling good research practices task force-5, Value Health, 15, 828, 10.1016/j.jval.2012.06.011 Briggs, 2012, Model parameter estimation and uncertainty: a report of the ISPOR-SMDM modeling good research practices task force-6, Value Health, 15, 835, 10.1016/j.jval.2012.04.014 Eddy, 2012, Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force-7, Value Health, 15, 843, 10.1016/j.jval.2012.04.012 Mandelblatt, 2009, Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms, Ann Intern Med, 151, 738, 10.7326/0003-4819-151-10-200911170-00010 Wijeysundera, 2010, Cost-effectiveness of specialized multidisciplinary heart failure clinics in Ontario, Canada, Value Health, 13, 915, 10.1111/j.1524-4733.2010.00797.x Shechter, 2005, A clinically based discrete-event simulation of end-stage liver disease and the organ allocation process, Med Decis Making, 25, 199, 10.1177/0272989X04268956 Sander, 2010, Is a mass immunization program for pandemic (H1N1) 2009 good value for money?, Vaccine, 28, 10, 10.1016/j.vaccine.2010.07.010 2010, Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis, Ont Health Technol Assess Ser [Internet], 10, 1 Ramwadhdoebe, 2009, A tutorial on discrete-event simulation for health policy design and decision making: optimizing pediatric ultrasound screening for hip dysplasia as an illustration, Health Policy, 93, 143, 10.1016/j.healthpol.2009.07.007 Philips, 2006, Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment, Pharmacoeconomics, 24, 355, 10.2165/00019053-200624040-00006 Philips, 2004, Review of guidelines for good practice in decision-analytic modelling in health technology assessment, Health Technol Assess, 8, 1, 10.3310/hta8360 Torrance, 1996, Framing and designing the cost-effectiveness analysis Erenay, 2011, Estimating the unknown parameters of the natural history of metachronous colorectal cancer using discrete-event simulation, Med Decis Making, 31, 611, 10.1177/0272989X10391809 1996 Neumann, 2009, Costing and perspective in published cost-effectiveness analysis, Med Care, 47, S28, 10.1097/MLR.0b013e31819bc09d Knox, 1980, Strategy for rubella vaccination, Int J Epidemiol, 9, 13, 10.1093/ije/9.1.13 Kim, 2008, Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches, Pharmacoeconomics, 26, 191, 10.2165/00019053-200826030-00004 Kelly, 1996, Cost-effectiveness of strategies to prevent neural tube defects Rutter, 2011, Dynamic microsimulation models for health outcomes: a review, Med Decis Making, 31, 10, 10.1177/0272989X10369005 Smith, 2009, Moving the QALY forward: rationale for change, Value Health, 12, S1, 10.1111/j.1524-4733.2009.00514.x Weinstein, 2009, QALYs: the basics, Value Health, 12, S5, 10.1111/j.1524-4733.2009.00515.x Kahneman, 2009, A different approach to health state valuation, Value Health, 12, S16 Eisenberg, 1989, Clinical economics: a guide to the economic analysis of clinical practices, JAMA, 262, 79, 10.1001/jama.1989.03430200123038 Ramsey, 2005, Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA task force report, Value Health, 8, 521, 10.1111/j.1524-4733.2005.00045.x 2006, Guidelines for the economic evaluation of health technologies: Canada Henry, 1992, Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals, Pharmacoeconomics, 1, 54, 10.2165/00019053-199201010-00010 Weinstein, 1987, Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model, Am J Pub Health, 77, 1417, 10.2105/AJPH.77.11.1417 2003 Matchar, 1997, The Stroke Prevention Policy Model: linking evidence and clinical decisions, Ann Intern Med, 127, 704, 10.7326/0003-4819-127-8_Part_2-199710151-00054 Baker, 2003, Quantitative analysis of sponsorship bias in economic studies of antidepressants, Br J Psychiatry, 183, 498, 10.1192/bjp.183.6.498 Bell, 2006, Bias in published cost effectiveness studies: systematic review, BMJ, 332, 699, 10.1136/bmj.38737.607558.80 Chauhan, 2007, Exploration of the difference in results of economic submissions to the National Institute of Clinical Excellence by manufacturers and assessment groups, Int J Technol Assess Health Care, 23, 96, 10.1017/S0266462307051628 Barbieri, 2001, Conflict of interest in industry-sponsored economic evaluations: real or imagined?, Curr Oncol Rep, 3, 410, 10.1007/s11912-001-0027-2 Strzalko, 2010, Understanding coin-tossing, Mathematical Intelligencer, 32, 54, 10.1007/s00283-010-9143-x Detsky, 1997, Primer on medical decision analysis, Part 1--getting started, Med Decis Making, 17, 123, 10.1177/0272989X9701700201 Helfand, 1997, Influence diagrams: a new dimension for decision models, Med Decis Making, 17, 351, 10.1177/0272989X9701700312 Nease, 1997, Use of influence diagrams to structure medical decisions, Med Decis Making, 17, 263, 10.1177/0272989X9701700302 Owens, 1997, Representation and analysis of medical decision problems with influence diagrams, Med Decis Making, 17, 241, 10.1177/0272989X9701700301 Novak, 2008 Ruiz-Primo, 1996, Problems and issues in the use of concept maps in science assessment, J Res Sci Teaching, 33, 569, 10.1002/(SICI)1098-2736(199608)33:6<569::AID-TEA1>3.0.CO;2-M Stahl, 2008, Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide, Pharmacoeconomics, 26, 131, 10.2165/00019053-200826020-00004 Barton, 2004, Modelling in the economic evaluation of health care: selecting the appropriate approach, J Health Serv Res Policy, 9, 110, 10.1258/135581904322987535 Freedberg, 1998, The cost-effectiveness of preventing AIDS-related opportunistic infections, JAMA, 279, 130, 10.1001/jama.279.2.130 Long, 2009, Potential population health outcomes and expenditures of HIV vaccination strategies in the United States, Vaccine, 27, 5402, 10.1016/j.vaccine.2009.06.063 Richter, 2005, Health and economic impacts of an HIV intervention in out of treatment substance abusers: evidence from a dynamic model, Health Care Manag Sci, 8, 67, 10.1007/s10729-005-5218-1 Leslie, 1990, The dynamics of HIV spread: a computer simulation model, Comput Biomed Res, 23, 380, 10.1016/0010-4809(90)90028-B Porco, 2001, Amplification dynamics: predicting the effect of HIV on tuberculosis outbreaks, J Acquir Immune Defic Syndr, 28, 437, 10.1097/00042560-200112150-00005 Auchincloss, 2008, A new tool for epidemiology: the usefulness of dynamic-agent models in understanding place effects on health, Am J Epidemiol, 168, 1, 10.1093/aje/kwn118 Linas, 2009, Improving outcomes in state AIDS drug assistance programs, J Acquir Immune Defic Syndr, 51, 513, 10.1097/QAI.0b013e3181b16d00 Zaric, 2000, HIV transmission and the cost-effectiveness of methadone maintenance, Am J Public Health, 90, 1100, 10.2105/AJPH.90.7.1100 Detsky, 1997, Primer on medical decision analysis, part 2--building a tree, Med Decis Making, 17, 126, 10.1177/0272989X9701700202 Carlson, 1985, Management of acute dysuria: a decision-analysis model of alternative strategies, Ann Intern Med, 102, 244, 10.7326/0003-4819-102-2-244 Krumholz, 1992, Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction, N Engl J Med, 327, 7, 10.1056/NEJM199207023270102 Clermont, 2004, In silico design of clinical trials: a method coming of age, Crit Care Med, 32, 2061, 10.1097/01.CCM.0000142394.28791.C3 Daun, 2008, Equation-based models of dynamic biological systems, J Crit Care, 23, 585, 10.1016/j.jcrc.2008.02.003 Kumar, 2008, A mathematical simulation of the inflammatory response to anthrax infection, Shock, 29, 104, 10.1097/SHK.0b013e318067dcfe Eddy, 2003, Validation of the Archimedes diabetes model, Diabetes Care, 26, 3102, 10.2337/diacare.26.11.3102 Schlessinger, 2002, Archimedes: a new model for simulating health care systems–the mathematical formulation, J Biomed Inform, 35, 37, 10.1016/S1532-0464(02)00006-0